TITLE

Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes

PUB. DATE
November 2008
SOURCE
Indian Journal of Ophthalmology;Nov2008, Vol. 56 Issue 6, p465
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
34972476

 

Related Articles

  • Patolojik Miyopiye BaÄŸlı Subfoveal Koroidal Neovaskülarizasyon GeliÅŸen Olgularda Fotodinamik Tedavi. Özkırış, Abdullah; Tuzcu, Esra Ayhan; Erkılıç, Kuddusi; İlhan, Özgır; Öner, Ayþe; Yarbağ, Abdılhekim; Pangal, Emine // Erciyes Medical Journal / Erciyes Tip Dergisi;2008, Vol. 30 Issue 4, p238 

    Purpose: To evaluate the outcomes of photodynamic therapy (PDT) with verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia. Materials and Methods: Eight eyes of 8 patients with subfoveal choroidal neovascular membran (CNV) due to pathologic myopia...

  • CNV due to uncommon causes responds variably to PDT. Guttman, Cheryl // Ophthalmology Times;11/15/2004, Vol. 29 Issue 22, p27 

    This article reports that outcomes of verteporfin photodynamic therapy in eyes with subfoveal choroidal neovascularization due to causes other than age-related macular degeneration and pathologic myopia are generally favorable, but vary by diagnosis. This was revealed at a prospective case...

  • Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularisation secondary to pathological myopia. Gibson, J. // Eye;Aug2005, Vol. 19 Issue 8, p829 

    Focuses on the use of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV). Efficacy of the use of laser photocoagulation in preventing loss of vision; Role of PDT and verteporfin CNV secondary to pathological myopia; Ability of PDT to treat patients with subfoveal...

  • Early data favor verteporfin therapy in OHS-related cases. Guttman, Cheryl; Saperstein, David A. // Ophthalmology Times;08/01/2000, Vol. 25 Issue 15, p23 

    Reports on the results of the six-month follow-up study of verteporfin therapy for subfoveal choroidal neovascularization secondary to ocular histoplasmosis syndrome (OHS). Potential of verteporfin therapy for treating eyes with OHS; Number of patients involved in the study; Procedure of the...

  • Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Lam, D. S. C.; Liu, D. T. L.; Fan, D. S. P.; Lai, W. W.; So, S. F.; Chan, W.-M. // Eye;Aug2005, Vol. 19 Issue 8, p834 

    Purpose: To study the efficacy of photodynamic therapy (PDT) with verteporfin in the treatment of juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia.Methods: Prospective, open label, two-centre, noncomparative, interventional case series....

  • Treatment of Subfoveal Choroidal Neovascularization Secondary to Choroidal Nevus Using Photodynamic Therapy. Levy, Jaime; Shneck, Marina; Klemperer, Itamar; Lifshitz, Tova // Ophthalmic Surgery, Lasers & Imaging;Jul/Aug2005, Vol. 36 Issue 4, p343 

    A 52-year-old man sought treatment for decreased vision in his right eye for 3 weeks. Visual acuity was 20/120. Examination revealed an elevated choroidal nevus at the posterior pole. Fluorescein and indocyanine green angiographies disclosed fibrovascular pigment epithelial detachment extending...

  • Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of I and 2 year follow up. Lam, D. S. C.; Chan, W.-M.; Liu, D. T. L.; Fan, D. S. P.; Lai, W. W.; Chong, K. K. L. // British Journal of Ophthalmology;Oct2004, Vol. 88 Issue 10, p1315 

    Aims: To evaluate the visual and fluorescein angiographic outcomes of photodynamic therapy (PDT) with verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia in the Chinese. Methods: Prospective, non-comparative, two centre interventional study....

  • PDT Outcomes Show Promise at Two Years.  // Review of Ophthalmology;Apr2001, Vol. 8 Issue 4, p107 

    Suggests that photodynamic therapy with verteporfin can safely reduce the risk of vision loss in patients with subfoveal choroidal neo-vascularization caused by age-related macular degeneration. Clinical trials at 22 opthalmic practices in Europe and North America; Outcome of the treatment...

  • Verteporfin PDT for non-standard indications—a review of current literature. Wai Man Chan; Tock-Han Lim; Pece, Alfredo; Silva, Rufino; Yoshimura, Nagahisa // Graefe's Archive of Clinical & Experimental Ophthalmology;May2010, Vol. 248 Issue 5, p613 

    Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT...

  • Visudyne.  // Royal Society of Medicine: Medicines;2002, p565 

    This article provides information on Visudyne, a proprietary, prescription-only preparation of the drug verteporfin from Novartis Ophthalmics. This drug be used for photodynamic treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration or with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics